Many genes represented in the 22 CpG panel also showed differences in gene expression as measured by the Illumina HumanHT-12 v3 Expression BeadChip (Illumina Inc.)comparing beadchip probe fluorescence intensities for tumor and normal tissue mRNA samples collected on the same OPSCC patients, including CDKN2A (expression probe ILMN_1717714), GPSM1 (ILMN_1709307), FLJ33790/KLHL35 (ILMN_1693471), and SYCP2 (probes ILMN_2095704 and ILMN_1765770) 11. This evidence concerns the gene CDKN2A and neoplasm.